Johnson & Johnson finally has some good news to report for its diabetes blockbuster Invokana, after the FDA approved a new cardiovascular outcome claim on its label. The US regulator has approved ...
Eli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease in a clinical trial, and is now on course to be the first to have a chronic heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results